News Owlstone's breath diagnostic to be used in asthma research Owlstone's ReCIVA and FAIMS technologies will be used to discover asthma-specific biomarkers.
News Owlstone's breath-based lung cancer diagnostic could save 10... Trial's next phase will recruit 3,000 patients across 21 international sites.
R&D Allogeneic cell therapy isn’t dead, with Brian Culley Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
